Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium
The first comprehensive international collaboration of randomized phase III clinical trial individual patient data.
“MARCAP allows the generation of the highest level of evidence for the optimal treatment for patients with prostate cancer.”
Created in 2020, MARCAP is the culmination of years of work from co-Principal Investigators, Dr. Dan Spratt and Dr. Amar Kishan. Inspired from analogous efforts in breast cancer from the EBCTCG, MARCAP finally can provide physicians and patients the data needed to deliver optimal prostate cancer care.
-
Dr. Daniel Spratt
Co-Principal Investigator
Chairman and Vincent K Smith Professor of the Department of Radiation Oncology at University Hospitals Seidman Cancer Center, and a Professor at Case Western Reserve University School of Medicine.
He is an international expert in clinical trial design, conduct, and analysis. He has led numerous advancements in the field of prostate cancer, runs an NIH funded translational lab, and has published over 300 peer-reviewed manuscripts.
-
Dr. Amar Kishan
Co-Principal Investigator
Associate Professor and Vice-Chair of Clinical and Translational Research for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center.
He is an international expert in the management and clinical research of prostate cancer. He studies advanced radiotherapy treatment techniques, and has published over 150 peer-reviewed manuscripts.
